Analyst Julian Harrison from BTIG maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) and keeping the price target at $8.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Julian Harrison has given his Buy rating due to a combination of factors surrounding VYNE Therapeutics’ development of VYN202. The initiation of the Phase 1b trial for VYN202 in treating moderate-to-severe plaque psoriasis shows promise, as the drug demonstrated a safe and favorable pharmacokinetic and pharmacodynamic profile in earlier trials. The ongoing trial is designed to evaluate both safety and preliminary efficacy, with topline results expected by the end of 2025, suggesting a well-conceived approach to tackling psoriasis and potentially other inflammatory conditions.
In addition, VYN202 is distinguished by its potent and selective action on the BD2 protein, which is associated with pro-inflammatory gene expression. This selectivity may enhance safety by minimizing off-target effects compared to other treatments. The drug’s efficacy in suppressing BD2 may translate into significant therapeutic benefits. Combined with a detailed valuation analysis, these factors contribute to a positive outlook for VYNE Therapeutics, supporting the Buy rating by Julian Harrison.
Harrison covers the Healthcare sector, focusing on stocks such as Rezolute, Cartesian Therapeutics, and VYNE Therapeutics. According to TipRanks, Harrison has an average return of 6.0% and a 44.59% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $5.75 price target.